Dual-qualified solicitor and Chartered Trade Mark Attorney, Chris Hoole, last month relocated to the Cambridge office of leading intellectual property firm Appleyard Lees.
Chris is looking forward to supporting existing and new clients in Cambridge, the UK and beyond, from his new home base.
Chris will continue his work to help build the national litigation and trade mark practices of Appleyard Lees, as the firm positions itself for further growth in years to come.
“Chris is a fantastic lawyer who will be a great resource for clients in and around Cambridge,” said Robert Cumming, Head of…
Laupheim, Germany; Milford, MA, USA and Cambridge, UK, 19 May 2020: Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Horizon Discovery, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the signing of a commercial license agreement. Under the terms of the agreement, Horizon’s CHOSOURCE™ platform will be used in combination with Rentschler Biopharma’s novel in-house process for cell line development for difficult-to-express proteins. Horizon’s gene-edited…
We are excited to announce the launch of our new webinar series called BIODATAlks, taking the format of 30-45 minute interactive conversations, and hosted by the BioData Innovation Centre team at the Wellcome Genome Campus.
The webinars feature a variety of genomics and biodata experts- from established companies to start-ups and academic spinouts. These online sessions are designed to introduce you to thought-leaders, founders, and experts who have created successful teams and enterprises in the biodata and genomics fields. With absolutely no pre-recorded content, speakers expect to have…
AMSBIO reports on the positive customer feedback received for their One-Step Luciferase Assay kit recently introduced for quantitation of firefly luciferase activity in mammalian cell culture.Dr Maja Petkovic, Custom Services Business Unit Manager at AMSBIO said "Initial uptake of this new kit has been strong particularly for high throughput screening applications. Our customers have appreciated that the kit offers not just high sensitivity but also the convenience of a homogeneous, single step protocol. In a recent study, researchers at Excellerate Bioscience (https://excelleratebio.…
In recent months, the world has faced its most significant peace-time crisis, effecting all corners of the globe. Like many others, we at PIR International have adopted new working practices to adapt and to continue to support our clients and candidates, who are developing lifesaving treatments and technologies for all diseases. We wish to take this opportunity to thank those developing these important medicines, diagnostics and those on the frontline in healthcare settings looking after all those in need, effected by COVID-19, but also all other diseases which continue to impact millions of…
Westbury, NY – May 11, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is adding high-purity Kupffer cells to its portfolio of human primary hepatic cells to support liver disease drug discovery and development and help predict adverse drug reactions.
Kupffer cells perform a scavenger role in the liver, removing small particles, senescent cells and cell debris. They also play an important role in the immune response to liver pathogens. Dysregulation of the Kupffer cell response contributes to chronic inflammation,…
The Greenshoots Podcast by Appleyard Lees gives listeners access to insights from leading intellectual property specialists.
The bi-weekly programme delivers practical, timely guidance to innovators, inventors and IP owners and managers.
Leading IP specialists discuss the most important topics in patents, trade marks, IP litigation and IP strategy, in real time.
Episode one features patent attorneys Adam Tindall, an engineer, and Richard Bray, a physicist, discussing IPO responses to COVID-19, navigating uncertainty in IP, new (and old) ways of working, sector-specific impacts, resurrecting…
Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
TREM-1, an immunoreceptor expressed on innate immune cells, has been identified by Inotrem as a key therapeutic target for many acute or chronic inflammation syndromes, including sepsis and…
AMSBIO has extended its COVID-19 research portfolio with the introduction of a service to provide custom lentivirus pseudotyped with spike glycoprotein from SARS-CoV-2 to help researchers identify potential targets for development of therapeutic drugs and vaccines. Various research groups around the world have demonstrated that SARS-CoV-2 uses its spike glycoprotein S, a main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry.In response to widespread demand, AMSBIO has developed a custom service to provide ready-to-use in…